2,3-二氢-2-[3-(4-硝基苯氧基)苯基]-1,3-二氧代-1H-异吲哚-5-羧酸 | 420841-84-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二氢-2-[3-(4-硝基苯氧基)苯基]-1,3-二氧代-1H-异吲哚-5-羧酸
• 英文名称: 2-(3-(4-Nitrophenoxy)phenyl)-1,3-dioxoisoindoline-5-carboxylic acid
• 英文别名: 2-[3-(4-nitrophenoxy)phenyl]-1,3-dioxoisoindole-5-carboxylic acid
• CAS: 420841-84-5
• 化学式: C21H12N2O7
• 分子量: 404.3
• InChiKey: HFYPTENHTPNXGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
  申请人：UTI Limited Partnership

  公开号：US20200215085A1

  公开（公告）日：2020-07-09

  Methods for prevention and treatment of asthma attacks involve the administration of one or more TRPV1 antagonists, one or more LPAr antagonists or preferably a combination of one or more TRPV1 antagonists and one or more LPAr antagonists. TRPV1 antagonists and/or LPAr antagonists or a combination of both inhibit or prevent carotid body activation during an acute asthma attack. TRPV1 antagonists, LPAr antagonists or a combination thereof are useful for preventing or ameliorating the symptoms of asthma attacks. Pharmaceutical compositions for use in treating asthma and more specifically for preventing or treating asthma attacks comprise a combination of a TRPV1 antagonist and an LPAr antagonist. Methods for making medicaments for such treatment are provided. Also provided are kits for treating asthma and for preventing or treating asthma attacks in which a TRPV1 antagonist and an LPAr antagonist are separately formulated for administration at the same time.
• [EN] MODULATION OF DENDRITIC CELL FUNCTION BY THE PHOSPHOLIPID MESSENGER LPA<br/>[FR] MODULATION DE LA FONCTION DES CELLULES DENDRITIQUES PAR LE MESSAGER DES PHOSPHOLIPIDES LPA
  申请人：UNIV CORNELL

  公开号：WO2021034414A2

  公开（公告）日：2021-02-25

  Described herein are compositions and methods that include use of PERK inhibitors, inhibitors of enzymes that can synthesize lysophosphatidic acid (LPA), inhibitors of LPA signaling, such as LPA receptor antagonists, deletion/mutation knockout/knockdown) or PERK or LPA receptors, or combinations thereof. Such compositions and methods can increase production of interferon by dendritic cells in subjects suffering from cancer and improve the survival of those subjects.